Xinlei (Ivan) Mi, Ph. D.
Assistant Professor, Biostatistics
Northwestern University
Email: xinlei.mi@northwestern.edu
[CV] [Github] [Google Scholar]
Education
Ph.D., 2018, Biostatistics, University of Florida (Advisor: Fei Zou)
Research Interest
Personalized Medicine, Comparative Effectiveness Analysis
Deep Learning, Machine Learning
High-Dimensional Data, Omics Data
Publications
Mi, X., Zou, F., and Zhu, R. (2018). Bagging and deep learning in optimal individualized treatment rules. Biometrics. [link] [R packages dnnet and ITRlearn] [Example]
Mi, X., Tighe, P., Zou, F., Zou, B. (2018). A deep learning semiparametric regression for adjusting complex confounding structures. (In review)
Mi, X., Zou, F., Zou, B., Hu, J. (2020). Permutation-based identification of important biomarkers for complex diseases via black-box models. (In review)
Collaboration
Yang G. S., Mi, X., Jackson-Cook, C. K., Starkweather, A. R., Kelly, D. L., Archer, K. J., Zou, F., Lyon, D.E. (2020). Differential DNA methylation following chemotherapy for breast cancer is associated with lack of memory improvement at one year. Epigenetics
Kirpich, A. S., Ibarra, M., Moskalenko, O., Fear, J. M., Gerken, J., Mi, X., Ashrafi, A., Morse, A. M., and McIntyre, L. M. (2018). Secimtools: a suite of metabolomics data analysis tools. BMC Bioinformatics
Slayton, W. B., Schultz, K. R., Kairalla, J. A., Devidas, M., Mi, X., Pulsipher, M. A., Chang, B. H., Mullighan, C., Iacobucci, I., Silverman, L. B., et al. (2018). Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: Results of children s oncology group trial aall0622. Journal of Clinical Oncology
Ewelukwa, O., Cabrera, R., Zou, F., and Mi, X. (2016). Epidemiology of hepatocellular cancer in Florida state. American Journal of Gastroenterology
Harrison, D. J., Parisi, M. T., Shulkin, B. L., Chi, Y.-Y., Anderson, J. R., Mi, X., Malempati, S., Mascarenhas, L., McCowage, G. B., Weigel, B., et al. (2016). 18f 2fluoro-2deoxy-d-glucose positron emission tomography (fdg-pet) response to predict event-free survival (efs) in intermediate risk (ir) or high risk (hr) rhabdomyosarcoma (rms): A report from the soft tissue sarcoma committee of the children s oncology group (cog). Journal of Clinical Oncology